REVIEW article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Application and Challenges of Tumor Organoid Technology in Precision Immunotherapy
Provisionally accepted
- 1Department of Orthopaedics of the First Affiliated Hospital, School of Medicine, Xi'an Jiaotong University, Xian, China
- 2School of Medicine, Xi'an Jiaotong University, Xian, China
- 3School of Public Health, Xi'an Jiaotong University, Xi’an, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
In recent years, tumor organoid technology has emerged as a crucial bridge connecting basic research and clinical applications with a deeper understanding of tumor biology. This technology enables reconstruction of tumor-native structures in vitro and their microenvironments, providing new possibilities for assessing individual responses and optimizing treatment strategies. This paper details the application prospects of organoid technology in tumor immune microenvironment reconstruction, personalized therapy, and drug screening. It also analyzes the current challenges faced by organoid technology in clinical translation, including model standardization, the integrity of immune microenvironment reconstruction, and the importance of interdisciplinary collaboration. Furthermore, we discuss how emerging technologies, such as 3D bioprinting and microfluidic chips, are driving advancements in tumor research. In the future, tumor organoid technology will used to support precision immunotherapy by establishing standardized processes and databases to enhance data comparability and reproducibility. creating a closed-loop system of "patient-organoid-multi-omics data-clinical decision support" will further promote the development of precision medicine and facilitate clinical application.
Keywords: immune microenvironment, Model standardization, personalized therapy, precision immunotherapy, tumor organoids
Received: 13 Oct 2025; Accepted: 02 Dec 2025.
Copyright: © 2025 Zhao, Gao, Liu, Shi, Zhang, Zhang and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Jinghong Chen
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.